Annual SG&A
$10.70 M
-$905.50 K-7.80%
31 December 2023
Summary:
Enveric Biosciences annual selling, general & administrative expenses is currently $10.70 million, with the most recent change of -$905.50 thousand (-7.80%) on 31 December 2023. During the last 3 years, it has risen by +$4.58 million (+74.71%). ENVB annual SG&A is now -50.52% below its all-time high of $21.62 million, reached on 31 December 2021.ENVB Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$1.24 M
-$62.00 K-4.78%
30 September 2024
Summary:
Enveric Biosciences quarterly selling, general & administrative expenses is currently $1.24 million, with the most recent change of -$62.00 thousand (-4.78%) on 30 September 2024. Over the past year, it has dropped by -$844.90 thousand (-40.61%). ENVB quarterly SG&A is now -88.19% below its all-time high of $10.46 million, reached on 31 December 2021.ENVB Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$399.21 M
-$9.86 M-2.53%
30 September 2024
Summary:
Enveric Biosciences TTM selling, general & administrative expenses is currently -$399.21 million, with the most recent change of -$9.86 million (-2.53%) on 30 September 2024. Over the past year, it has dropped by -$410.34 million (-3688.74%). ENVB TTM SG&A is now -70569.43% below its all-time high of $21.66 million, reached on 31 December 2021.ENVB TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENVB Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -7.8% | -40.6% | -3688.7% |
| 3 y3 years | +74.7% | -41.8% | -2697.9% |
| 5 y5 years | -0.9% | -57.4% | -3480.0% |
ENVB Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -50.5% | +74.7% | -88.2% | at low | -551.0% | at low |
| 5 y | 5 years | -50.5% | +74.7% | -88.2% | +189.7% | -551.0% | at low |
| alltime | all time | -50.5% | >+9999.0% | -88.2% | +397.0% | <-9999.0% | at low |
Enveric Biosciences Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.24 M(-4.8%) | $6.89 M(-10.9%) |
| June 2024 | - | $1.30 M(-32.9%) | $7.74 M(-20.3%) |
| Mar 2024 | - | $1.93 M(-20.3%) | $9.71 M(-9.5%) |
| Dec 2023 | $10.70 M(-7.8%) | $2.43 M(+16.6%) | $10.73 M(-3.6%) |
| Sept 2023 | - | $2.08 M(-36.4%) | $11.12 M(-11.4%) |
| June 2023 | - | $3.27 M(+11.0%) | $12.56 M(+6.5%) |
| Mar 2023 | - | $2.95 M(+4.5%) | $11.79 M(+1.6%) |
| Dec 2022 | $11.61 M(-46.3%) | $2.82 M(-19.7%) | $11.61 M(-39.7%) |
| Sept 2022 | - | $3.51 M(+40.5%) | $19.24 M(+7.8%) |
| June 2022 | - | $2.50 M(-9.6%) | $17.85 M(+1.1%) |
| Mar 2022 | - | $2.77 M(-73.5%) | $17.66 M(-18.5%) |
| Dec 2021 | $21.62 M(+253.1%) | $10.46 M(+392.6%) | $21.66 M(+41.0%) |
| Sept 2021 | - | $2.12 M(-8.0%) | $15.37 M(+12.4%) |
| June 2021 | - | $2.31 M(-65.9%) | $13.67 M(+13.2%) |
| Mar 2021 | - | $6.77 M(+62.5%) | $12.08 M(+46.7%) |
| Dec 2020 | $6.12 M(-49.8%) | $4.16 M(+876.5%) | $8.23 M(+14.3%) |
| Sept 2020 | - | $426.50 K(-40.5%) | $7.20 M(-25.6%) |
| June 2020 | - | $716.60 K(-75.5%) | $9.68 M(-21.0%) |
| Mar 2020 | - | $2.92 M(-6.7%) | $12.26 M(+0.4%) |
| Dec 2019 | $12.21 M(+13.1%) | $3.13 M(+8.0%) | $12.21 M(+3.4%) |
| Sept 2019 | - | $2.90 M(-11.9%) | $11.81 M(+2.1%) |
| June 2019 | - | $3.30 M(+14.6%) | $11.56 M(+7.1%) |
| Mar 2019 | - | $2.88 M(+5.2%) | $10.79 M(-0.0%) |
| Dec 2018 | $10.79 M(-41.7%) | $2.74 M(+3.0%) | $10.79 M(-17.0%) |
| Sept 2018 | - | $2.66 M(+5.2%) | $13.01 M(-18.9%) |
| June 2018 | - | $2.52 M(-12.3%) | $16.04 M(-12.6%) |
| Mar 2018 | - | $2.88 M(-41.8%) | $18.36 M(-0.8%) |
| Dec 2017 | $18.51 M(+97.7%) | $4.95 M(-12.9%) | $18.51 M(+7.6%) |
| Sept 2017 | - | $5.69 M(+17.5%) | $17.20 M(+32.5%) |
| June 2017 | - | $4.84 M(+59.6%) | $12.98 M(+26.6%) |
| Mar 2017 | - | $3.03 M(-16.8%) | $10.25 M(+14.3%) |
| Dec 2016 | $9.36 M(+60.3%) | $3.64 M(+149.0%) | $8.97 M(+68.4%) |
| Sept 2016 | - | $1.46 M(-30.7%) | $5.33 M(-0.6%) |
| June 2016 | - | $2.11 M(+20.7%) | $5.36 M(+43.4%) |
| Mar 2016 | - | $1.75 M(+16.9%) | $3.74 M(+86.9%) |
| Dec 2015 | $5.84 M(>+9900.0%) | - | - |
| Sept 2015 | - | $1.50 M(+205.8%) | $2.00 M(+295.6%) |
| June 2015 | - | $489.70 K(>+9900.0%) | $505.50 K(+1738.2%) |
| Mar 2015 | - | $2300.00(-77.9%) | $27.50 K(-16.2%) |
| Dec 2014 | $32.80 K(+20.6%) | $10.40 K(+235.5%) | $32.80 K(-10.1%) |
| Sept 2014 | - | $3100.00(-73.5%) | $36.50 K(-3.9%) |
| June 2014 | - | $11.70 K(+53.9%) | $38.00 K(+25.8%) |
| Mar 2014 | - | $7600.00(-46.1%) | $30.20 K(+10.6%) |
| Dec 2013 | $27.20 K(+19.8%) | $14.10 K(+206.5%) | $27.30 K(+17.7%) |
| Sept 2013 | - | $4600.00(+17.9%) | $23.20 K(0.0%) |
| June 2013 | - | $3900.00(-17.0%) | $23.20 K(-0.9%) |
| Mar 2013 | - | $4700.00(-53.0%) | $23.40 K(+3.1%) |
| Dec 2012 | $22.70 K(-27.7%) | $10.00 K(+117.4%) | $22.70 K(-11.7%) |
| Sept 2012 | - | $4600.00(+12.2%) | $25.70 K(+3.6%) |
| June 2012 | - | $4100.00(+2.5%) | $24.80 K(+2.1%) |
| Mar 2012 | - | $4000.00(-69.2%) | $24.30 K(-22.6%) |
| Dec 2011 | $31.40 K(-12.5%) | $13.00 K(+251.4%) | $31.40 K(+5.4%) |
| Sept 2011 | - | $3700.00(+2.8%) | $29.80 K(-6.0%) |
| June 2011 | - | $3600.00(-67.6%) | $31.70 K(-2.8%) |
| Mar 2011 | - | $11.10 K(-2.6%) | $32.60 K(-9.2%) |
| Dec 2010 | $35.90 K | $11.40 K(+103.6%) | $35.90 K(-20.8%) |
| Sept 2010 | - | $5600.00(+24.4%) | $45.30 K(+2.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2010 | - | $4500.00(-68.8%) | $44.20 K(-17.1%) |
| Mar 2010 | - | $14.40 K(-30.8%) | $53.30 K(-4.1%) |
| Dec 2009 | $55.60 K(-63.3%) | $20.80 K(+362.2%) | $55.60 K(-20.3%) |
| Sept 2009 | - | $4500.00(-66.9%) | $69.80 K(-4.4%) |
| June 2009 | - | $13.60 K(-18.6%) | $73.00 K(-25.1%) |
| Mar 2009 | - | $16.70 K(-52.3%) | $97.40 K(-35.7%) |
| Dec 2008 | $151.40 K(-28.0%) | $35.00 K(+354.5%) | $151.40 K(-457.1%) |
| Sept 2008 | - | $7700.00(-79.7%) | -$42.40 K(-209.3%) |
| June 2008 | - | $38.00 K(-46.3%) | $38.80 K(-78.9%) |
| Mar 2008 | - | $70.70 K(-144.5%) | $183.50 K(-12.6%) |
| Dec 2007 | $210.40 K(-60.2%) | -$158.80 K(-278.6%) | $210.00 K(-59.9%) |
| Sept 2007 | - | $88.90 K(-51.3%) | $524.30 K(-6.0%) |
| June 2007 | - | $182.70 K(+88.0%) | $557.60 K(+10.3%) |
| Mar 2007 | - | $97.20 K(-37.5%) | $505.70 K(-4.2%) |
| Dec 2006 | $528.10 K(-35.8%) | $155.50 K(+27.3%) | $528.10 K(-11.5%) |
| Sept 2006 | - | $122.20 K(-6.6%) | $596.90 K(-6.2%) |
| June 2006 | - | $130.80 K(+9.4%) | $636.60 K(-15.3%) |
| Mar 2006 | - | $119.60 K(-46.7%) | $751.70 K(-8.6%) |
| Dec 2005 | $822.60 K(+9.2%) | $224.30 K(+38.5%) | $822.60 K(+5.9%) |
| Sept 2005 | - | $161.90 K(-34.2%) | $776.50 K(-0.6%) |
| June 2005 | - | $245.90 K(+29.1%) | $781.40 K(+2.3%) |
| Mar 2005 | - | $190.50 K(+6.9%) | $763.60 K(+1.4%) |
| Dec 2004 | $753.30 K(-35.7%) | $178.20 K(+6.8%) | $753.40 K(-13.0%) |
| Sept 2004 | - | $166.80 K(-26.9%) | $865.90 K(-12.2%) |
| June 2004 | - | $228.10 K(+26.5%) | $985.90 K(-9.8%) |
| Mar 2004 | - | $180.30 K(-38.0%) | $1.09 M(-6.7%) |
| Dec 2003 | $1.17 M(-8.3%) | $290.70 K(+1.4%) | $1.17 M(-6.3%) |
| Sept 2003 | - | $286.80 K(-14.6%) | $1.25 M(-3.6%) |
| June 2003 | - | $335.70 K(+29.9%) | $1.30 M(+2.1%) |
| Mar 2003 | - | $258.50 K(-30.1%) | $1.27 M(-0.6%) |
| Dec 2002 | $1.28 M(+8.0%) | $370.00 K(+10.8%) | $1.28 M(+5.8%) |
| Sept 2002 | - | $334.00 K(+8.2%) | $1.21 M(+3.2%) |
| June 2002 | - | $308.70 K(+16.2%) | $1.17 M(-1.2%) |
| Mar 2002 | - | $265.70 K(-11.5%) | $1.18 M(+0.1%) |
| Dec 2001 | $1.18 M(+12.2%) | $300.10 K(+1.3%) | $1.18 M(-4.2%) |
| Sept 2001 | - | $296.20 K(-8.2%) | $1.24 M(+2.0%) |
| June 2001 | - | $322.60 K(+21.9%) | $1.21 M(+5.5%) |
| Mar 2001 | - | $264.60 K(-24.8%) | $1.15 M(+8.8%) |
| Dec 2000 | $1.06 M(+36.5%) | $351.90 K(+29.5%) | $1.06 M(+50.0%) |
| Sept 2000 | - | $271.80 K(+4.6%) | $703.30 K(+63.0%) |
| June 2000 | - | $259.80 K(+51.3%) | $431.50 K(+151.3%) |
| Mar 2000 | - | $171.70 K(-359.4%) | $171.70 K(-93.9%) |
| Dec 1999 | $772.90 K(-71.7%) | - | - |
| Dec 1998 | $2.73 M(-22.6%) | -$66.20 K(-107.4%) | $2.83 M(-29.7%) |
| Sept 1998 | - | $900.00 K(-25.0%) | $4.03 M(+5.2%) |
| June 1998 | - | $1.20 M(+50.0%) | $3.83 M(+11.7%) |
| Mar 1998 | - | $800.00 K(-29.2%) | $3.43 M(-2.8%) |
| Dec 1997 | $3.53 M(-17.6%) | $1.13 M(+61.4%) | $3.53 M(+77.9%) |
| Sept 1997 | - | $700.00 K(-12.5%) | $1.98 M(-28.7%) |
| June 1997 | - | $800.00 K(-11.1%) | $2.78 M(-30.1%) |
| Mar 1997 | - | $900.00 K(-316.3%) | $3.98 M(-7.0%) |
| Dec 1996 | $4.28 M(-4.8%) | -$416.10 K(-127.7%) | $4.28 M(-8.9%) |
| Sept 1996 | - | $1.50 M(-25.0%) | $4.70 M(+46.9%) |
| June 1996 | - | $2.00 M(+66.7%) | $3.20 M(+166.7%) |
| Mar 1996 | - | $1.20 M | $1.20 M |
| Dec 1995 | $4.50 M(+246.2%) | - | - |
| Dec 1994 | $1.30 M(-27.8%) | - | - |
| Aug 1994 | $1.80 M | - | - |
FAQ
- What is Enveric Biosciences annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Enveric Biosciences?
- What is Enveric Biosciences annual SG&A year-on-year change?
- What is Enveric Biosciences quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Enveric Biosciences?
- What is Enveric Biosciences quarterly SG&A year-on-year change?
- What is Enveric Biosciences TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Enveric Biosciences?
- What is Enveric Biosciences TTM SG&A year-on-year change?
What is Enveric Biosciences annual selling, general & administrative expenses?
The current annual SG&A of ENVB is $10.70 M
What is the all time high annual SG&A for Enveric Biosciences?
Enveric Biosciences all-time high annual selling, general & administrative expenses is $21.62 M
What is Enveric Biosciences annual SG&A year-on-year change?
Over the past year, ENVB annual selling, general & administrative expenses has changed by -$905.50 K (-7.80%)
What is Enveric Biosciences quarterly selling, general & administrative expenses?
The current quarterly SG&A of ENVB is $1.24 M
What is the all time high quarterly SG&A for Enveric Biosciences?
Enveric Biosciences all-time high quarterly selling, general & administrative expenses is $10.46 M
What is Enveric Biosciences quarterly SG&A year-on-year change?
Over the past year, ENVB quarterly selling, general & administrative expenses has changed by -$844.90 K (-40.61%)
What is Enveric Biosciences TTM selling, general & administrative expenses?
The current TTM SG&A of ENVB is -$399.21 M
What is the all time high TTM SG&A for Enveric Biosciences?
Enveric Biosciences all-time high TTM selling, general & administrative expenses is $21.66 M
What is Enveric Biosciences TTM SG&A year-on-year change?
Over the past year, ENVB TTM selling, general & administrative expenses has changed by -$410.34 M (-3688.74%)